monoclonal antibody huJ591

Known as: MOAB huJ591, huJ591 
A humanized monoclonal antibody (MoAb) against the external domain of the Prostate-specific membrane antigen (PSMA), overexpressed in the malignant… (More)
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
Antibodies, and engineered antibody fragments, labeled with radioisotopes are being developed as radiotracers for the detection… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
PURPOSE Standard imaging for assessing osseous metastases in advanced prostate cancer remains focused on altered bone metabolism… (More)
Is this relevant?
2014
2014
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
Given the bone tropism of prostate cancer, conventional imaging modalities poorly identify or quantify metastatic disease. 89Zr… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
Engineered antibody fragments offer faster delivery with retained tumor specificity and rapid clearance from nontumor tissues… (More)
Is this relevant?
Review
2013
Review
2013
Prostate-specific membrane antigen-based imaging.
Prostate cancer (CaP) is the most common noncutaneous malignancy affecting men in North America. Despite significant efforts… (More)
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 2
Is this relevant?
Review
2009
Review
2009
New targeted probes for radioimaging of angiogenesis.
Angiogenesis, the formation of new blood vessels, is a multi-step process regulated by pro- and anti-angiogenic factors. In order… (More)
Is this relevant?
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… (More)
Is this relevant?
2004
2004
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
BACKGROUND Prostate specific membrane antigen (PSMA), expressed by virtually all prostate cancers is an ideal target for targeted… (More)
Is this relevant?
Review
2004
Review
2004
Radioimmunotherapy of prostate cancer.
In recent years, advances in the rational design of radiopharmaceuticals have helped in the introduction of clinically useful… (More)
Is this relevant?
Review
2003
Review
2003
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
PURPOSE Prostate specific membrane antigen (PSMA) is a cell surface peptidase highly expressed by malignant prostate epithelial… (More)
Is this relevant?